Itameline

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Itameline ( ; developmental code name RU-47213) is a non-selective muscarinic acetylcholine receptor agonist nootropic drug which was under development for the treatment of Alzheimer's disease and memory disorders but was never marketed. Itameline is a prodrug of an arecoline derivative. It is an agonist of the muscarinic acetylcholine M 1 receptor as well as of other muscarinic acetylcholine receptors. Itameline is described as being superior to arecoline in terms of potency, central selectivity, and duration of action. The drug shows antiamnesic effects in animals, for instance reversing scopolamine-induced memory deficits. Structurally, it is a tetrahydropyridine similarly to xanomeline and milameline. Itameline was first described in the scientific literature by 1992. It was under development by Hoechst Marion Roussel and reached phase 2 clinical trials by 1998 prior to discontinuation of development.

Itameline ( ; developmental code name RU-47213) is a non-selective muscarinic acetylcholine receptor agonist nootropic drug which was under development for the treatment of Alzheimer's disease and memory disorders but was never marketed. Itameline is a prodrug of an arecoline derivative. It is an agonist of the muscarinic acetylcholine M 1 receptor as well as of other muscarinic acetylcholine receptors. Itameline is described as being superior to arecoline in terms of potency, central selectivity, and duration of action. The drug shows antiamnesic effects in animals, for instance reversing scopolamine-induced memory deficits. Structurally, it is a tetrahydropyridine similarly to xanomeline and milameline. Itameline was first described in the scientific literature by 1992. It was under development by Hoechst Marion Roussel and reached phase 2 clinical trials by 1998 prior to discontinuation of development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377240028 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.